Aim - to study the peculiarities of lipid and coagulation abnormalities in high risk patients, and also the possibilities of their correction with statin therapy. Methods. 102 patients were studied, 1 group included patients with LDL 3.0-3.9 mmol/l (n=59), who received atorvastatin 40 mg daily with titration to 80 mg daily, 2 group - patients with LDL >4.0 mmol/l (n=48), who received rosuvastatin 10 mg daily with titration to 20 mg daily. Results. In the 1 group of patients, after 24 weeks mean LDL level decreased by 43.3% (p<0.001), 51 patients (94.4%) achieved target level of LDL. In the 2 group, mean LDL level decreased by 50.6% (p<0.001), 43 patients achieved target level of LDL. The mean level of Willebrand factor (vWf) (127.1+21.9% in the 1 group and 124 + 34.8% in the 2 group) and D-dimer (1.0+0.6 pg/ml in the 1 group and 0.9 + 0.5 pg/ml in the 2 group) was higher than before treatment. In the patients of the 1 group, after 24 weeks of treatment fibrinogen levels decreased by 19.1% (p<0,001), vWf-by 20.5% (p<0,001). D-dimer levels - by 12% (p=0,046). Fibrinogen levels in the patients of the 2 group decreased by 23.5% (p<0,001), vWf - by 31.6% (p<0,001), D-dimer -by 33.3% (p=0,01) and starting time of ADF induced platelet aggregation increased by 11.8% (p=0,008). Conclusions. Patients at high risk of cardiovascular death show the rise of vWf and D-dimer levels along with dyslipidemia. Statin treatment during 24 weeks leads to achievement of target levels of LDL, decreasing of endothelial dysfunction and also thrombogenic potential of the blood.